Gossamer Bio completes exchange of 94.5% of 2027 notes; $18.9M remain outstanding

Gossamer Bio, Inc.

$181.1M principal (94.5%) of 5% 2027 notes tendered; exchanged for new 7.5% 2030 notes and equity.
Company lowered tender condition from 98% to 90.5% after sufficient early participation by June 2.
Early settlement occurred June 4; supplemental indenture eliminated restrictive covenants.
No additional notes tendered after early date; $18.9M of existing notes remain outstanding.
New 7.5% secured first lien notes due 2030, plus up to 317.6M shares or prefunded warrants issued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.